Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 5;15:163. doi: 10.1186/s13045-022-01376-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 6 — CAR.CD123-NK cells maintain efficacy and safety profile in an AML xenograft animal model based on hIL15-NOG mice. A hIL15-NOG mice were systemically engrafted with THP-1-FF-Luc.GFP cells and, at the time of leukaemia engraftment, treated or not with NT-NK and CAR.CD123-NK cells. Time course of in vivo bioluminescence imaging of the treated NOG mice. B Fifty-day probability of OS for NSG mice systemically infused with THP-1-FF-Luc.GFP cells after adoptive transfer of NT-NK (blue bars with circles) or CAR.123-NK cells (red bars with squares). The untreated control is represented by a black line with triangles. C Flow cytometry analysis of human NK cells in PB of mice (n = 5 mice receiving NK-NT; n = 5 mice receiving CAR.CD123-NK) performed at Day 15 and Day 30 after effector cell infusion. Plots show the percentage of hCD45⁺ hCD56⁺ hCD3⁻ cells gated on the total cells present in PB of the mice (left panel) and as the percentage of hCD45⁺ hCD16⁺ cells of the total hCD45⁺ hCD56⁺ CD3.⁻ cells present in PB of the mice (right panel). Data are shown as average ± SD. *p < 0.05. D Cytokine concentration was measured in the plasma of mice bearing THP-1-FF-Luc.GFP cells and treated with NT-NK (grey bars) and CAR.CD123-NK (black line bars) cells at Day 15 and at Day 30 after effector cell infusion. Granz B, IFN-γ and TNF-α were measured by ELISA assay, and data are shown as average ± SD. *p < 0.05, **p < 0.01